| Literature DB >> 24650806 |
Mark R Villwock1, Amit Singla, David J Padalino, Eric M Deshaies.
Abstract
OBJECTIVES: Many physicians debate the efficacy of mechanical thrombectomy for ischaemic stroke, but most agree that to establish potential benefit, patient selection must be examined further. People >80 years are a growing population of patients with ischaemic stroke but are largely excluded from clinical trials. The benefit of thrombectomy for them may be greatly reduced due to diminishing neuroplasticity and a larger number of medical comorbidities. To address this knowledge gap, we examined clinical and economic outcomes after mechanical thrombectomy in the ischaemic stroke population from the Nationwide Inpatient Sample. Our null hypotheses were that elderly patients (>80 years) would have a similar rate of inpatient mortality in comparison to their younger counterparts and incur a similar economic expense.Entities:
Keywords: Health Economics; Vascular Surgery
Mesh:
Year: 2014 PMID: 24650806 PMCID: PMC3963096 DOI: 10.1136/bmjopen-2013-004480
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Patient-level and hospital-level characteristics of the population receiving mechanical thrombectomy for acute ischaemic stroke compared between the elderly and their younger counterpart
| ≤80 years (n=7614 cases) | >80 years (n=1686 cases) | p Value | |
|---|---|---|---|
| Age | 63 (53–73) | 84 (82–87) | |
| Gender, female | 46.9% | 66.7% | <0.001 |
| Race, Caucasian | 60.2% | 67.6% | 0.013 |
| Median income level | |||
| <US$39 000 | 26.7% | 23.5% | 0.607 |
| US$39 000–$47 999 | 24.8% | 25.6% | |
| US$48 000–$62 999 | 23.6% | 23.5% | |
| ≥US$63 000 | 24.9% | 27.4% | |
| Payer, Medicare | 44.9% | 90.5% | <0.001 |
| Elixhauser comorbidity score | |||
| ≤2 | 37.2% | 30.6% | <0.001 |
| 3 | 21.7% | 26.5% | |
| ≥4 | 41.1% | 42.9% | |
| APR-DRG severity of illness | |||
| Mild | 0% | 0% | 0.418 |
| Moderate | 1.5% | 0.6% | |
| Major | 53.5% | 53.9% | |
| Extreme | 45% | 45.5% | |
| Thrombolysis (intravenous or intra-arterial) | 55.5% | 63.1% | 0.013 |
| Length of stay, days (survivors) | 9 (5–14) | 9 (6–13.6) | 0.711 |
| Length of stay, days (all patients) | 8 (4–13) | 8 (4–12) | 0.004 |
| Total charges, US$ (survivors) | 137 692 (95 139–207 687) | 137 756 (87 582–198 103) | 0.021 |
| Total charges, US$ (all patients) | 132 828 (90 661–205 835) | 126 238 (86 230–188 294) | <0.001 |
| Discharged home | 12.7% | 2.1% | <0.001 |
| Inpatient mortality | 21.6% | 33.7% | <0.001 |
| Hospital owner | |||
| Government, non-federal | 22.6% | 18.8% | 0.150 |
| Private, non-profit | 69.2% | 74.6% | |
| Private, investor-owned | 8.2% | 6.6% | |
| Teaching hospital | 84.2% | 80.6% | 0.122 |
Continuous variables expressed as median (25th centile–75th centile).
APR-DRG, All Patient Refined–Diagnosis Related Group.
Figure 1Multivariate analysis of inpatient mortality and economic measures for survivors. Inpatient mortality expressed as the OR along with the 95% CI derived from binary logistic regression. Length of stay and charges are both expressed using the exponential parameter estimate along with the 95% CI derived from generalised estimating equations. p Values are adjacent to the 95% CIs. Points to the right of 1.0 reflect an increase in the odds/effect ratio relative to the indicated reference category. Points to the left of 1.0 reflect a decrease in the odds/effect ratio relative to the indicated reference category.